The Indian Vaccine Manufacturers Association (IVMA) has appointed Dr. Krishna M Ella as its new President for a two-year term from April 2024-2026. Dr. Ella, a renowned scientist and entrepreneur, is known for his work in biotechnology and leadership in the industry. He will lead the Association in advancing vaccine development and production.
Dr. Ella takes over from Mr. Adar C Poonawala, who held the post from 2019 to March 2024. The current Vice President is Ms. Mahima Datla, Managing Director of Biological E, with Mr. T. Srinivas as Treasurer and Dr. Harshavardhan as Director General of IVMA.
Dr. Ella emphasized the importance of global health and ensuring access to vaccines for all individuals. He aims to promote innovation, sustainability, and equity within the industry to protect public health in India and other developing countries.
His appointment comes at a crucial time when the world faces emerging infectious diseases and the need for preventative vaccine research is urgent. Under his leadership, IVMA plans to enhance collaboration among vaccine manufacturers, researchers, and policymakers to accelerate vaccine development and production.
IVMA’s mission is to address the concerns of Indian vaccine manufacturers and streamline regulatory processes. They aim to maintain their status as a global hub for high-quality vaccines at affordable prices.
IVMA was founded in 2010 by Dr. Krishna M. Ella and includes prominent vaccine manufacturers like Bharat Biotech, Serum Institute of India, Biological E, and Panacea Biotec. Indian Immunologicals Ltd recently joined the association in April 2024.
For more information about IVMA, visit their website at http://ivma.in/.
